BRPI0413740A - composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo - Google Patents
composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativoInfo
- Publication number
- BRPI0413740A BRPI0413740A BRPI0413740-0A BRPI0413740A BRPI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A
- Authority
- BR
- Brazil
- Prior art keywords
- oxide
- pharmaceutically acceptable
- acceptable salt
- compound
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
"COMPOSTO OU UM SEU N-óXIDO OU SEU SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO, E, MéTODO DE TRATAMENTO DE DISTúRBIO HIPERPROLIFERATIVO". Compostos representados pela fórmula (I): ou um seu N-óxido ou seu sal farmaceuticamente aceitável, são úteis no tratamento de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49677603P | 2003-08-21 | 2003-08-21 | |
PCT/US2004/026483 WO2005021544A2 (en) | 2003-08-21 | 2004-08-16 | N3-substituted imidazopyridine-derivatives as c-kit inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413740A true BRPI0413740A (pt) | 2006-10-24 |
Family
ID=34272515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413740-0A BRPI0413740A (pt) | 2003-08-21 | 2004-08-16 | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1658289B1 (pt) |
JP (1) | JP2007502822A (pt) |
KR (1) | KR20060119871A (pt) |
CN (1) | CN1839132A (pt) |
AP (1) | AP2006003552A0 (pt) |
AR (1) | AR045388A1 (pt) |
AT (1) | ATE425977T1 (pt) |
AU (1) | AU2004268950A1 (pt) |
BR (1) | BRPI0413740A (pt) |
CA (1) | CA2536174A1 (pt) |
DE (1) | DE602004020073D1 (pt) |
IL (1) | IL173615A0 (pt) |
IS (1) | IS8318A (pt) |
MX (1) | MXPA06002019A (pt) |
MY (1) | MY138737A (pt) |
NO (1) | NO20060670L (pt) |
RU (1) | RU2006108799A (pt) |
SG (1) | SG131944A1 (pt) |
TW (1) | TW200519111A (pt) |
WO (1) | WO2005021544A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
SG190620A1 (en) | 2008-05-05 | 2013-06-28 | Sanofi Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
EP2308877B1 (en) * | 2008-08-05 | 2014-01-22 | Daiichi Sankyo Company, Limited | Imidazopyridin-2-one derivatives |
WO2010045276A2 (en) * | 2008-10-16 | 2010-04-22 | Cara Therapeutics, Inc. | Azabenzimidazolones |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
RU2619463C2 (ru) * | 2009-12-30 | 2017-05-16 | Аркьюл, Инк. | Замещенные имидазопиридинил-аминопиридиновые соединения, полезные при лечении рака |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
JP6046710B2 (ja) * | 2011-06-24 | 2016-12-21 | アーキュール,インコーポレイティド | 置換されたイミダゾピリジニル−アミノピリジン化合物 |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
PL2935248T3 (pl) * | 2012-12-21 | 2018-07-31 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania dla nich |
DK3122748T3 (en) * | 2014-03-24 | 2018-11-05 | Arqule Inc | METHOD OF PREPARING 3- (3- (4- (1-AMINOCYCLOBUTYL) PHENYL) -5-PHENYL-3H-IMIDAZO [4,5-B] PYRIDIN-2-YL) PYRIDIN-2-AMINE |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
TW251284B (pt) * | 1992-11-02 | 1995-07-11 | Pfizer | |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
WO2001057020A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
AU2002334355A1 (en) * | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
-
2004
- 2004-08-16 DE DE602004020073T patent/DE602004020073D1/de active Active
- 2004-08-16 SG SG200702982-0A patent/SG131944A1/en unknown
- 2004-08-16 MX MXPA06002019A patent/MXPA06002019A/es unknown
- 2004-08-16 AU AU2004268950A patent/AU2004268950A1/en not_active Abandoned
- 2004-08-16 CA CA002536174A patent/CA2536174A1/en not_active Abandoned
- 2004-08-16 JP JP2006523956A patent/JP2007502822A/ja active Pending
- 2004-08-16 WO PCT/US2004/026483 patent/WO2005021544A2/en active Application Filing
- 2004-08-16 KR KR1020067003586A patent/KR20060119871A/ko not_active Application Discontinuation
- 2004-08-16 CN CNA2004800240419A patent/CN1839132A/zh active Pending
- 2004-08-16 RU RU2006108799/04A patent/RU2006108799A/ru not_active Application Discontinuation
- 2004-08-16 AP AP2006003552A patent/AP2006003552A0/xx unknown
- 2004-08-16 AT AT04781205T patent/ATE425977T1/de not_active IP Right Cessation
- 2004-08-16 EP EP04781205A patent/EP1658289B1/en active Active
- 2004-08-16 BR BRPI0413740-0A patent/BRPI0413740A/pt not_active IP Right Cessation
- 2004-08-20 MY MYPI20043423A patent/MY138737A/en unknown
- 2004-08-20 AR ARP040103009A patent/AR045388A1/es not_active Application Discontinuation
- 2004-08-20 TW TW093125235A patent/TW200519111A/zh unknown
-
2006
- 2006-02-08 IL IL173615A patent/IL173615A0/en unknown
- 2006-02-10 NO NO20060670A patent/NO20060670L/no not_active Application Discontinuation
- 2006-02-21 IS IS8318A patent/IS8318A/is unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007502822A (ja) | 2007-02-15 |
SG131944A1 (en) | 2007-05-28 |
KR20060119871A (ko) | 2006-11-24 |
WO2005021544A3 (en) | 2005-06-16 |
CA2536174A1 (en) | 2005-03-10 |
NO20060670L (no) | 2006-05-12 |
WO2005021544A2 (en) | 2005-03-10 |
IS8318A (is) | 2006-02-21 |
AR045388A1 (es) | 2005-10-26 |
AP2006003552A0 (en) | 2006-04-30 |
AU2004268950A1 (en) | 2005-03-10 |
MY138737A (en) | 2009-07-31 |
ATE425977T1 (de) | 2009-04-15 |
IL173615A0 (en) | 2006-07-05 |
EP1658289B1 (en) | 2009-03-18 |
TW200519111A (en) | 2005-06-16 |
MXPA06002019A (es) | 2006-05-31 |
CN1839132A (zh) | 2006-09-27 |
RU2006108799A (ru) | 2006-07-27 |
DE602004020073D1 (de) | 2009-04-30 |
EP1658289A2 (en) | 2006-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413746A (pt) | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo | |
BRPI0413785A (pt) | composto, composição, e, método de tratamento de distúrbio hiperproliferativo | |
BRPI0413740A (pt) | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo | |
BR0214485A (pt) | 3-cianoquinolinas como inibidores de egf-r e her2 quinases | |
BRPI0411365A (pt) | derivados de aminopiridina | |
HK1085675A1 (en) | Anticancer compounds | |
BRPI0416605A (pt) | composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica | |
BR0316487A (pt) | Método todo de tratamento da rejeição de transplantes | |
CY1109245T1 (el) | Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα | |
CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
MXPA04002537A (es) | Alquinos como inhibidores de metaloproteinasa de matriz. | |
BRPI0518794A2 (pt) | composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
ATE452896T1 (de) | C3-cyanoepothilonderivate | |
DK1056704T3 (da) | Antitumormidler | |
WO2004110151A8 (en) | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments | |
SE0301320D0 (sv) | Positive modulators of nicotinic acetylcholine receptors | |
BR0312470A (pt) | Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto | |
MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
NO20055998L (no) | Diarylmetylidenpiperidinderivater, preparater derav og anvendelse derav | |
BRPI0409768A (pt) | composto, uso de composto, composição farmacêutica, método para tratar e/ou prevenir cáncer, e, processo para preparar o composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |